ClinicalTrials.gg
Enrolling by invitationNCT07437924Updated Mar 12, 2026

Bruxism and Pelvic Floor Dysfunction in Young Women

An observational study in Bruxism, Pelvic Floor Disorder and Young Adult Females, sponsored by Akdeniz University. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Akdeniz University · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 30 Years
Sex
Female
01

Study summary

Bruxism and Pelvic Floor Dysfunction in Young Women

Read the detailed description

Bruxism and Pelvic Floor Dysfunction in Young Women: A Cross-Sectional Questionnaire Study Examining the Relationship Between Orofacial Parafunction and Pelvic Floor Symptoms

02

Conditions studied

  • Bruxism
  • Pelvic Floor Disorder
  • Young Adult Females
  • Myofascial Pain Dysfunction Syndrome
  • TMJ Pain

Keywords

  • bruxism
  • pelvic floor dysfuctions
  • myofascial problems
03

In context

Bruxism

151 studies on the registry are indexed under Bruxism; 39 are open to participants now.

This study's planned enrollment of 100 is above the median of 89 across 55 observational studies indexed under Bruxism.

Browse Bruxism studies →

Lead sponsor

Akdeniz University is the lead sponsor of 297 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Female individuals aged 18-30 years

-Voluntary agreement to participate in the study and approval of the online informed consent form

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female individuals aged 18-30 years
  • Voluntary agreement to participate in the study and approval of the online form

For the bruxism group:

  • Self-reported teeth clenching and/or grinding behavior during wakefulness or sleep within the past 6 months
  • Presence of clinical findings supporting bruxism (e.g., tooth wear patterns, masseter/temporalis muscle tenderness) identified during a clinical examination conducted at the Faculty of Dentistry

For the non-bruxism group:

  • No self-reported teeth clenching or grinding behavior
  • Absence of clinical findings supporting bruxism upon examination

Bruxism classification will be performed in accordance with the current international consensus, based on self-report combined with clinical findings, within the framework of "probable bruxism" (Verhoeff et al., 2025).

Exclusion criteria

Exclusion Criteria:

  • Diagnosed temporomandibular joint (TMJ) dysfunction or significant jaw pain syndromes
  • History of major pelvic surgery; early postpartum period (\<1 year) or current pregnancy
  • Neurological disorders (e.g., multiple sclerosis, peripheral neuropathies)
  • Presence of active urogenital or colorectal infection/disease
  • Diagnosed pelvic floor pathologies (e.g., advanced pelvic organ prolapse, severe urinary/fecal incontinence)
  • Chronic use of opioids, anticholinergic agents, or muscle relaxants
  • Severe psychiatric disorders (e.g., diagnosed major depressive disorder, generalized anxiety disorder)
  • Receipt of any bruxism-related treatment within the past 6 months (e.g., occlusal splint therapy, botulinum toxin injections, intensive physiotherapy)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Target follow-up
50 Months
Patient registry
Yes

Groups and cohorts

  • Bruxism Group

    Women who has bruksizm

    Diagnostic Test: Questionnaire and Physical Exam

  • Non-bruksizm Group

    Control group

    Diagnostic Test: Questionnaire and Physical Exam

Interventions

  • Diagnostic testQuestionnaire and Physical Exam

    20 mins questionnaire survey

06

What researchers measure

Primary outcomes

  1. Bruxism Assessment Section

    Sleep and awake bruxism will be evaluated according to the bruxism diagnostic criteria established by the American Academy of Sleep Medicine (AASM) in 2023. Bruxism-related pain will be subjectively assessed using the Visual Analog Scale (VAS). The Visual Analogue Scale (VAS) is a 10-cm used to measure pain intensity, where 0 represents "no pain" and 10 represents the "worst imaginable pain. Patients mark their pain level, which is measured in cm or mm to determine the score.

    Time frame: 6 months

  2. Jaw Function Assessment Section

    Jaw function will be evaluated using the Jaw Functional Limitation Scale-20 (JFLS-20). The Jaw Functional Limitation Scale-20 (JFLS-20) scores range from 0 to 200 (or 0-10 average per item), with higher scores indicating more severe jaw functional limitation. It measures 20 items across three constructs-mastication, vertical mobility, and verbal/emotional expression-using a 0-10 scale, with 0 meaning "no limitation" and 10 meaning "severe limitation

    Time frame: 6 months

  3. Pelvic Floor Assessment Section

    Pelvic floor symptoms will be assessed using the Pelvic Floor Distress Inventory-20 (PFDI-20) and the relevant items of the Pelvic Pain Impact Questionnaire. The Pelvic Floor Distress Inventory-20 (PFDI-20) is a questionnaire measuring the severity of pelvic floor dysfunction, with total scores ranging from 0 to 300 (0 = no distress, 300 = maximum distress). It includes three subscales-POPDI-6, UDI-6, and CRADI-8-each scored from 0 to 100, calculated by multiplying the mean of answered items (0-4) by 25

    Time frame: 6 months

Secondary outcomes

  1. Anxiety Assessment Section

    Anxiety levels will be assessed using the State-Trait Anxiety Inventory (STAI - State Anxiety Scale). The State-Trait Anxiety Inventory (STAI-S) assesses temporary, immediate, or situation-specific anxiety using a 20-item self-report questionnaire with 4-point Likert-type responses. Scores range from 20 to 80, with higher scores indicating higher levels of anxiety. A cutoff of 39-40 is often used for detecting clinically significant symptoms.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Verhoeff MC, Lobbezoo F, Ahlberg J, Bender S, Bracci A, Colonna A, Dal Fabbro C, Durham J, Glaros AG, Haggman-Henrikson B, Kato T, Koutris M, Lavigne GJ, Nykanen L, Raphael KG, Svensson P, Wieckiewicz M, Manfredini D. Updating the Bruxism Definitions: Report of an International Consensus Meeting. J Oral Rehabil. 2025 Sep;52(9):1335-1342. doi: 10.1111/joor.13985. Epub 2025 May 1. PubMed 40312776 ↗
  • Sulowska-Daszyk I, Gamrot S, Handzlik-Waszkiewicz P. A Single Session of Temporomandibular Joint Soft Tissue Therapy and Its Effect on Pelvic Floor Muscles Activity in Women-A Randomized Controlled Trial. J Clin Med. 2024 Nov 21;13(23):7037. doi: 10.3390/jcm13237037. PubMed 39685496 ↗
  • Minguez-Esteban I, De-la-Cueva-Reguera M, Romero-Morales C, Martinez-Pascual B, Navia JA, Bravo-Aguilar M, Abuin-Porras V. Physical manifestations of stress in women. Correlations between temporomandibular and pelvic floor disorders. PLoS One. 2024 Apr 16;19(4):e0296652. doi: 10.1371/journal.pone.0296652. eCollection 2024. PubMed 38626037 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Apr 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Feb 27, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Apr 16, 2026
CompletionEst.
May 15, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07437924
Lead sponsor
Akdeniz University
Collaborators
Konya Necmettin Erbakan Üniversitesi, Bilecik Seyh Edebali Universitesi
Responsible party
Alime Buyuk (PhD,Akdeniz University, Physiotherapy and Rehabilitation Department, Akdeniz University) — Principal investigator
First posted
Feb 27, 2026
Start date
Feb 16, 2026
Primary completion
Apr 16, 2026 (estimated)
Completion
May 15, 2026 (estimated)
Last update
Mar 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion